Abstract
RNA interference (RNAi) is an efficient process of posttranscriptional gene silencing. In recent years it has been developed into a new technology in biopharmaceutical fields of science. RNAi products include short interference RNA (siRNA) but also short hairpin RNA (shRNA), bifunctional short hairpin RNA (bi-shRNA) and microRNA (miRNA). They combine with homologous fragments of the mRNA and cause its degradation. It results in inhibition of protein synthesis, or in mutation in the gene encoding it. RNAi has been used in analysis of genomes and creation of new animal models to test drugs. From the pharmaceutical point of view, what is the most important is its therapeutic application. So far the basic and clinical research has been focused on the following targets: macular degeneration, cancer and antiviral therapy. But there are also reports on clinical trials in asthma, hypercholesterolemia and genetic diseases such as inherited skin disorders and amyloidosis. Among over 20 therapeutics that reached clinical trials, only few are still investigated. Another few are clinical candidates. The review focuses on RNAi products under clinical evaluation and their most promising new applications.
Keywords: Cancer, clinical trials, miRNA, post-transcriptional gene silencing, RNA interference, RNAi-based therapies, siRNA.
Current Medicinal Chemistry
Title:RNAi in Clinical Studies
Volume: 20 Issue: 14
Author(s): P. Kubowicz, D. Zelaszczyk and E. Pekala
Affiliation:
Keywords: Cancer, clinical trials, miRNA, post-transcriptional gene silencing, RNA interference, RNAi-based therapies, siRNA.
Abstract: RNA interference (RNAi) is an efficient process of posttranscriptional gene silencing. In recent years it has been developed into a new technology in biopharmaceutical fields of science. RNAi products include short interference RNA (siRNA) but also short hairpin RNA (shRNA), bifunctional short hairpin RNA (bi-shRNA) and microRNA (miRNA). They combine with homologous fragments of the mRNA and cause its degradation. It results in inhibition of protein synthesis, or in mutation in the gene encoding it. RNAi has been used in analysis of genomes and creation of new animal models to test drugs. From the pharmaceutical point of view, what is the most important is its therapeutic application. So far the basic and clinical research has been focused on the following targets: macular degeneration, cancer and antiviral therapy. But there are also reports on clinical trials in asthma, hypercholesterolemia and genetic diseases such as inherited skin disorders and amyloidosis. Among over 20 therapeutics that reached clinical trials, only few are still investigated. Another few are clinical candidates. The review focuses on RNAi products under clinical evaluation and their most promising new applications.
Export Options
About this article
Cite this article as:
Kubowicz P., Zelaszczyk D. and Pekala E., RNAi in Clinical Studies, Current Medicinal Chemistry 2013; 20 (14) . https://dx.doi.org/10.2174/09298673113209990118
DOI https://dx.doi.org/10.2174/09298673113209990118 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chinese Herbal Medicine for Hyperlipidaemia: A Review Based on Data Mining from 1990 to 2016
Current Vascular Pharmacology Treatment of Disorders Characterized by Reversible Airway Obstruction in Childhood: are Anti-cholinergic Agents the Answer?
Current Pharmaceutical Design New Genetic and Pharmacological Treatments for Cystic Fibrosis
Current Pediatric Reviews Endothelins Role in the Control of the Acute Phase of Trypanosoma cruzi Infection
Mini-Reviews in Medicinal Chemistry Thermostable Subunit Vaccines for Pulmonary Delivery: How Close Are We?
Current Pharmaceutical Design Current Status Of Short Synthetic Peptides As Vaccines
Medicinal Chemistry B Cells and Beyond: Therapeutic Opportunities Targeting Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Higher Expression of NOD1 and NOD2 is Associated with Vogt-Koyanagi-Harada (VKH) Syndrome But Not Behcet’s Disease (BD)
Current Molecular Medicine Editorial [Hot Topic: Oxidative Balance: Experimental and Clinical Perspectives (Executive Editor: Fortunato Vesce)]
Current Pharmaceutical Design Cytokine Therapeutics for Asthma: An Appraisal of Current Evidence and Future Prospects
Current Pharmaceutical Design The Search for the Genetic Component of COPD: Role of the Clinical Phenotype
Current Respiratory Medicine Reviews The Role of Lymphotoxin Receptor Signaling in Diseases
Current Molecular Medicine Editorial: [Monoclonal Antibodies in the Treatment of Asthma(Guest Editor: Moshe Ben-Shoshan)]
Recent Patents on Inflammation & Allergy Drug Discovery Past, Present and Future of Electroanalytical Sensor for Aspirin, Ibuprofen and Paracetamol Detection
Current Pharmaceutical Analysis Pharmacological Screening of Lantana camara for its Antiallergic Activity in Rodents
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Pharmacogenomics and Personalized Medicine for the Developing World - Too Soon or Just-in-Time? A Personal View from the World Health Organization
Current Pharmacogenomics and Personalized Medicine Bicyclic 6 + 6 Systems: Advances in the Chemistry of Heterocyclic Compounds Incorporated Pyrimido[1,2-a]Pyrimidine Skeleton
Mini-Reviews in Organic Chemistry The Epidemiology and Health Effects of Tobacco Smoke Exposure
Current Pediatric Reviews Towards Isozyme-Selective HDAC Inhibitors For Interrogating Disease
Current Topics in Medicinal Chemistry Induction of Oral Tolerance with Transgenic Plants Expressing Antigens for Prevention/Treatment of Autoimmune, Allergic and Inflammatory Diseases
Current Pharmaceutical Biotechnology